Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia

October 9, 2017

Dilutions of compounds was performed using a TECAN D300e Digital Dispenser from 10 mM stocks

The BCL-2 family protein BAX is a central mediator of apoptosis. Overexpression of anti-apoptotic BCL-2 proteins contributes to tumor development and resistance to therapy by suppressing BAX and its activators. We report the discovery of BTSA1, a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. BTSA1-induced BAX activation effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells. BAX expression levels and cytosolic conformation regulate sensitivity to BTSA1. BTSA1 potently suppressed human acute myeloid leukemia (AML) xenografts and increased host survival without toxicity. This study provides proof-of-concept for direct BAX activation as a treatment strategy in AML. Copyright Š 2017 Elsevier Inc. All rights reserved.

Reyna, DE; Garner, TP; Lopez, A; Kopp, F; Choudhary, GS; Sridharan, A; Narayanagari, SR; Mitchell, K; Dong, B; Bartholdy, BA; Walensky, LD; Verma, A; Steidl, U; Gavathiotis, E;

Journal: Cancer Cell Pages: 490-505.e10

Original article (29017059)